Asia Pacific Cardiac Resynchronization Therapy Market Size & Outlook
- MedTech
- Cardiovascular Devices
- Cardiac Resynchronization Therapy Market Outlook
- Cardiovascular Devices
Global Report
Related Markets
Ask a question about the cardiac resynchronization therapy market
Asia Pacific cardiac resynchronization therapy market highlights
- The Asia Pacific cardiac resynchronization therapy market generated a revenue of USD 884.5 million in 2025.
- The market is expected to grow at a CAGR of 6.6% from 2026 to 2033.
- In terms of segment, crt-defibrillator was the largest revenue generating product in 2025.
- CRT-Pacemaker is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2026 to 2033.
Asia Pacific data book summary
| Market revenue in 2025 | USD 884.5 million |
| Market revenue in 2033 | USD 1,480.5 million |
| Growth rate | 6.6% (CAGR from 2026 to 2033) |
| Largest segment | Crt-defibrillator |
| Fastest growing segment | CRT-Pacemaker |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | CRT-Defibrillator, CRT-Pacemaker |
| Key market players worldwide | Medtronic PLC, Abbott Laboratories, Boston Scientific Corp, BIOTRONIK, MicroPort Scientific Corp, LivaNova PLC |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 17.5% of the cardiac resynchronization therapy market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,480.5 million by 2033.
Asia Pacific is projected to grow at fastest CAGR over the next few years. This is owing to developing healthcare infrastructure, aging population, improvement in economic conditions, strategic initiatives by key companies, and growing prevalence of cardiac diseases. Developed markets, such as Japan and Australia, are also rapidly adopting new technological advancements in these devices.
For instance, remote monitoring in cardiac implantable devices was found to be adopted rapidly across Asia Pacific, especially in CRT/CRTDs, despite having greater cost. In New Zealand, data on cardiac implantable electronic devices was studied between 2014 and 2017. 155 patients received CRT-D implants, while 175 received CRT-P implants during the period.
No credit card required*
Publish Date: Nov 11, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cardiac Resynchronization Therapy Market Scope
Cardiac Resynchronization Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| Medtronic PLC | View profile | 95,000 | Lower Hatch Street, 20 On Hatch, Dublin, Ireland, 2 | www.medtronic.com |
| Boston Scientific Corp | View profile | 48,000 | 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234 | www.bostonscientific.com |
| LivaNova PLC | View profile | 2,900 | 20 Eastbourne Terrace, London, United Kingdom, W2 6LG | www.livanova.com |
| BIOTRONIK | View profile | 5001-10000 | Berlin, Berlin, Germany, Europe | www.biotronik.com/de-de |
| MicroPort Scientific Corp | View profile | 8,230 | 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Shanghai, China, People's Republic of, 201203 | www.microport.com |
Asia Pacific Cardiac Resynchronization Therapy Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cardiac Resynchronization Therapy Market Outlook will help companies and investors design strategic landscapes.
Crt-Defibrillator was the largest segment with a revenue share of 59.92% in 2025.
Horizon Databook has segmented the Asia Pacific cardiac resynchronization therapy market based on crt-defibrillator, crt-pacemaker covering the revenue growth of each sub-segment from 2021 to 2033.
Asia Pacific is projected to grow at fastest CAGR over the next few years. This is owing to developing healthcare infrastructure, aging population, improvement in economic conditions, strategic initiatives by key companies, and growing prevalence of cardiac diseases. Developed markets, such as Japan and Australia, are also rapidly adopting new technological advancements in these devices.
For instance, remote monitoring in cardiac implantable devices was found to be adopted rapidly across Asia Pacific, especially in CRT/CRTDs, despite having greater cost. In New Zealand, data on cardiac implantable electronic devices was studied between 2014 and 2017. 155 patients received CRT-D implants, while 175 received CRT-P implants during the period.
- Asia Pacific Cardiac Resynchronization Therapy Market Product Outlook (Revenue, USD Million , 2021-2033)
- CRT-Defibrillator
- CRT-Pacemaker
- Asia Pacific Cardiac Resynchronization Therapy Market End-Use Outlook (Revenue, USD Million , 2021-2033)
- Hospitals
- Cardiac Centers
- Others
Reasons to subscribe to Cardiac Resynchronization Therapy Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cardiac Resynchronization Therapy Market Outlook databook
- Our clientele includes a mix of Cardiac Resynchronization Therapy Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Cardiac Resynchronization Therapy Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Cardiac Resynchronization Therapy Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Asia Pacific Cardiac Resynchronization Therapy Market, 2021-2033 (US$M)
Asia Pacific cardiac resynchronization therapy market statistics, by product, 2021-2033 (US$M)
